AGLagilon health, inc.

$95.65

AGL as reported

agilon health, inc. reported $5.82B of revenue over the trailing twelve months, −2.8% on the year before. 9 reported series are charted on this page, each one as filed.

$5.82B

Revenue, trailing twelve months · to Q1 2026 · −2.8% against the twelve months before

Net Income
−$355M

Net Income · +47% year on year · trailing twelve months to Q1 2026

Free Cash Flow
−$63M

Free Cash Flow · +12% year on year · trailing twelve months to Q1 2026

Op Margin
−7.4%

Op Margin · trailing twelve months to Q1 2026

Every series Ryufin has for AGL, trailing twelve months
SeriesLatestYear on yearAs of
Revenue$5.82B−2.8%Q1 2026
Net Income−$355M+47%Q1 2026
EPS$1.96+1682%Q1 2026
Op Margin−7.4%n/aQ1 2026
Net Margin−5.9%n/aQ1 2026
ROE−171%n/aQ1 2026
ROA−23%n/aQ1 2026
ROIC571%n/aQ1 2026
Free Cash Flow−$63M+12%Q1 2026

Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.

Revenue & Profitagilon health, inc. (AGL)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com